Better Therapeutics, Inc. (BTTX)
| Previous close | 0.0113 |
| Open | 0.0113 |
| Bid | 0.0360 x 800 |
| Ask | 0.0370 x 1400 |
| Day's range | 0.0096 - 0.0113 |
| 52-week range | 0.0050 - 1.3500 |
| Volume | |
| Avg. volume | 5,890,790 |
| Market cap | 545,156 |
| Beta (5Y monthly) | 2.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1000 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.25 |
Business WireBetter Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
SAN FRANCISCO, March 14, 2024--Better Therapeutics, Inc. (NASDAQ: BTTX) (the "Company") announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was made at a special meeting of the board of directors on Wednesday evening, March 13, 2024. Further, as previously disclosed, the Company’s securities are subject to delisting from the Nasdaq Stock Market unl
Business WireBetter Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers
SAN FRANCISCO, March 05, 2024--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine’s (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.
Business WireBetter Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
SAN FRANCISCO, March 04, 2024--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), to be held from March 6 to 9, 2024, in Florence, Italy. ATTD serves as a premier international forum showcasing c
